- Home
- ATCH vs QLGN Comparison
ATCH vs QLGN Comparison
Compare ATCH & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- QLGN
- Stock Information
- Founded
- ATCH 2022
- QLGN 1996
- Country
- ATCH United States
- QLGN United States
- Employees
- ATCH N/A
- QLGN N/A
- Industry
- ATCH
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- QLGN Health Care
- Exchange
- ATCH Nasdaq
- QLGN Nasdaq
- Market Cap
- ATCH 2.9M
- QLGN 3.1M
- IPO Year
- ATCH N/A
- QLGN N/A
- Fundamental
- Price
- ATCH $0.39
- QLGN $2.10
- Analyst Decision
- ATCH
- QLGN
- Analyst Count
- ATCH 0
- QLGN 0
- Target Price
- ATCH N/A
- QLGN N/A
- AVG Volume (30 Days)
- ATCH 20.1M
- QLGN 42.8K
- Earning Date
- ATCH 09-05-2025
- QLGN 08-14-2025
- Dividend Yield
- ATCH N/A
- QLGN N/A
- EPS Growth
- ATCH N/A
- QLGN N/A
- EPS
- ATCH N/A
- QLGN N/A
- Revenue
- ATCH $14,825,966.00
- QLGN N/A
- Revenue This Year
- ATCH N/A
- QLGN N/A
- Revenue Next Year
- ATCH N/A
- QLGN N/A
- P/E Ratio
- ATCH N/A
- QLGN N/A
- Revenue Growth
- ATCH 1066.77
- QLGN N/A
- 52 Week Low
- ATCH $0.14
- QLGN $1.61
- 52 Week High
- ATCH $26.94
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- ATCH 76.54
- QLGN 56.76
- Support Level
- ATCH $0.17
- QLGN $1.66
- Resistance Level
- ATCH $0.24
- QLGN $2.16
- Average True Range (ATR)
- ATCH 0.03
- QLGN 0.11
- MACD
- ATCH 0.02
- QLGN 0.08
- Stochastic Oscillator
- ATCH 87.28
- QLGN 87.17
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.